{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:02:24Z","timestamp":1775588544479,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["116283"],"award-info":[{"award-number":["116283"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00125-024-06126-3","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:37:57Z","timestamp":1710981477000},"page":"1328-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness and safety of empagliflozin: final results from the EMPRISE study"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-8306","authenticated-orcid":false,"given":"Phyo T.","family":"Htoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-2813","authenticated-orcid":false,"given":"Helen","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-467X","authenticated-orcid":false,"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-402X","authenticated-orcid":false,"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan M.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-8996","authenticated-orcid":false,"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Schmedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"D\u00e9ruaz-Luyet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-5445","authenticated-orcid":false,"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-9898","authenticated-orcid":false,"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"1","key":"6126_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S et al (2015) Association of cardiometabolic multimorbidity with mortality. JAMA 314(1):52\u201360. https:\/\/doi.org\/10.1001\/jama.2015.7008","journal-title":"JAMA"},{"issue":"22","key":"6126_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"16","key":"6126_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","journal-title":"N Engl J Med"},{"issue":"15","key":"6126_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/nejmoa2022190","journal-title":"N Engl J Med"},{"issue":"1","key":"6126_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-020-01133-1","volume":"19","author":"E D'Andrea","year":"2020","unstructured":"D\u2019Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Patorno E (2020) Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 19(1):154. https:\/\/doi.org\/10.1186\/s12933-020-01133-1","journal-title":"Cardiovasc Diabetol"},{"issue":"10166","key":"6126_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(18)32590-x","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"issue":"1","key":"6126_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/dom.14870","volume":"25","author":"T Nystr\u00f6m","year":"2023","unstructured":"Nystr\u00f6m T, Toresson Grip E, Gunnarsson J et al (2023) Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: real world evidence from the Nordic EMPRISE study. Diabetes Obes Metab 25(1):261\u2013271. https:\/\/doi.org\/10.1111\/dom.14870","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6126_CR8","doi-asserted-by":"publisher","first-page":"101418","DOI":"10.1016\/j.diabet.2022.101418","volume":"49","author":"A Karasik","year":"2023","unstructured":"Karasik A, Lanzinger S, Chia-Hui Tan E et al (2023) Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab 49(2):101418. https:\/\/doi.org\/10.1016\/j.diabet.2022.101418","journal-title":"Diabetes Metab"},{"issue":"10","key":"6126_CR9","doi-asserted-by":"publisher","first-page":"e2237606","DOI":"10.1001\/jamanetworkopen.2022.37606","volume":"5","author":"PT Htoo","year":"2022","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S et al (2022) Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open 5(10):e2237606. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37606","journal-title":"JAMA Netw Open"},{"key":"6126_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ahj.2022.09.008","volume":"254","author":"RJ Desai","year":"2022","unstructured":"Desai RJ, Glynn RJ, Everett BM et al (2022) Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. Am Heart J 254:203\u2013215. https:\/\/doi.org\/10.1016\/j.ahj.2022.09.008","journal-title":"Am Heart J"},{"issue":"25","key":"6126_CR11","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/circulationaha.118.039177","volume":"139","author":"E Patorno","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM et al (2019) Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation 139(25):2822\u20132830. https:\/\/doi.org\/10.1161\/circulationaha.118.039177","journal-title":"Circulation"},{"issue":"3","key":"6126_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.14593","volume":"24","author":"E Patorno","year":"2022","unstructured":"Patorno E, Pawar A, Wexler DJ et al (2022) Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab 24(3):442\u2013454. https:\/\/doi.org\/10.1111\/dom.14593","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6126_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D'Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E (2023) Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med 183(3):242\u2013254. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6664","journal-title":"JAMA Intern Med"},{"issue":"24","key":"6126_CR14","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/eurheartj\/ehad273","volume":"44","author":"EL Fu","year":"2023","unstructured":"Fu EL, Patorno E, Everett BM et al (2023) Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. Eur Heart J 44(24):2216\u20132230. https:\/\/doi.org\/10.1093\/eurheartj\/ehad273","journal-title":"Eur Heart J"},{"issue":"1","key":"6126_CR15","doi-asserted-by":"publisher","first-page":"e00103","DOI":"10.1002\/edm2.103","volume":"3","author":"E Patorno","year":"2020","unstructured":"Patorno E, Najafzadeh M, Pawar A et al (2020) The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab 3(1):e00103. https:\/\/doi.org\/10.1002\/edm2.103","journal-title":"Endocrinol Diabetes Metab"},{"issue":"10","key":"6126_CR16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/jamainternmed.2017.3844","volume":"177","author":"AJ Karter","year":"2017","unstructured":"Karter AJ, Warton EM, Lipska KJ et al (2017) Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use. JAMA Int Med 177(10):1461. https:\/\/doi.org\/10.1001\/jamainternmed.2017.3844","journal-title":"JAMA Int Med"},{"key":"6126_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1471-2288-11-157","volume":"11","author":"WV Bobo","year":"2011","unstructured":"Bobo WV, Cooper WO, Epstein RA Jr, Arbogast PG, Mounsey J, Ray WA (2011) Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. BMC Med Res Methodol 11:157. https:\/\/doi.org\/10.1186\/1471-2288-11-157","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"6126_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0895-4356(98)00161-9","volume":"52","author":"KM Newton","year":"1999","unstructured":"Newton KM, Wagner EH, Ramsey SD et al (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52(3):199\u2013207. https:\/\/doi.org\/10.1016\/s0895-4356(98)00161-9","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"6126_CR19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1681\/asn.2006010073","volume":"17","author":"SS Waikar","year":"2006","unstructured":"Waikar SS, Wald R, Chertow GM et al (2006) Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 17(6):1688\u20131694. https:\/\/doi.org\/10.1681\/asn.2006010073","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"6126_CR20","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/jbmr.3807","volume":"34","author":"NC Wright","year":"2019","unstructured":"Wright NC, Daigle SG, Melton ME, Delzell ES, Balasubramanian A, Curtis JR (2019) The design and validation of a new algorithm to identify incident fractures in administrative claims data. J Bone Miner Res 34(10):1798\u20131807. https:\/\/doi.org\/10.1002\/jbmr.3807","journal-title":"J Bone Miner Res"},{"issue":"5","key":"6126_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10552-007-0131-1","volume":"18","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S (2007) Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 18(5):561\u2013569. https:\/\/doi.org\/10.1007\/s10552-007-0131-1","journal-title":"Cancer Causes Control"},{"issue":"11","key":"6126_CR22","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1161\/strokeaha.114.006316","volume":"45","author":"SA Jones","year":"2014","unstructured":"Jones SA, Gottesman RF, Shahar E, Wruck L, Rosamond WD (2014) Validity of hospital discharge diagnosis codes for stroke: the Atherosclerosis Risk in Communities Study. Stroke 45(11):3219\u20133225. https:\/\/doi.org\/10.1161\/strokeaha.114.006316","journal-title":"Stroke"},{"issue":"1","key":"6126_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148(1):99\u2013104. https:\/\/doi.org\/10.1016\/j.ahj.2004.02.013","journal-title":"Am Heart J"},{"issue":"5","key":"6126_CR24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","volume":"43","author":"E Birman-Deych","year":"2005","unstructured":"Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43(5):480\u2013485. https:\/\/doi.org\/10.1097\/01.mlr.0000160417.39497.a9","journal-title":"Med Care"},{"issue":"1","key":"6126_CR25","first-page":"45","volume":"64","author":"ME Hill","year":"2001","unstructured":"Hill ME, Rosenwaike I (2001) The Social Security Administration\u2019s Death Master File: the completeness of death reporting at older ages. Soc Secur Bull 64(1):45\u201351","journal-title":"Soc Secur Bull"},{"key":"6126_CR26","unstructured":"Research Data Assistance Center (ResDAC) (2020) Death information in the Research Identifiable Medicare Data. Available from https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data2021. Accessed 20 Mar 2023"},{"issue":"5","key":"6126_CR27","doi-asserted-by":"publisher","first-page":"e004966","DOI":"10.1161\/jaha.116.004966","volume":"6","author":"OT Olubowale","year":"2017","unstructured":"Olubowale OT, Safford MM, Brown TM et al (2017) Comparison of expert adjudicated coronary heart disease and cardiovascular disease mortality with the national death index: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. J Am Heart Assoc 6(5):e004966. https:\/\/doi.org\/10.1161\/jaha.116.004966","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"6126_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S (2011) A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 64(7):749\u2013759. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"6126_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","volume":"75","author":"DH Kim","year":"2020","unstructured":"Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ (2020) Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data. J Gerontol A Biol Sci Med Sci 75(6):1120\u20131125. https:\/\/doi.org\/10.1093\/gerona\/glz224","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"6126_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41","journal-title":"Biometrika"},{"issue":"9","key":"6126_CR31","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/aje\/kwy078","volume":"187","author":"JE Ripollone","year":"2018","unstructured":"Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM (2018) Implications of the propensity score matching paradox in pharmacoepidemiology. Am J Epidemiol 187(9):1951\u20131961. https:\/\/doi.org\/10.1093\/aje\/kwy078","journal-title":"Am J Epidemiol"},{"issue":"6","key":"6126_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/clpt.2011.235","volume":"90","author":"S Schneeweiss","year":"2011","unstructured":"Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90(6):777\u2013790. https:\/\/doi.org\/10.1038\/clpt.2011.235","journal-title":"Clin Pharmacol Ther"},{"issue":"25","key":"6126_CR33","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"issue":"10","key":"6126_CR34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","volume":"33","author":"JM Franklin","year":"2014","unstructured":"Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S (2014) Metrics for covariate balance in cohort studies of causal effects. Stat Med 33(10):1685\u20131699. https:\/\/doi.org\/10.1002\/sim.6058","journal-title":"Stat Med"},{"key":"6126_CR35","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2011","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2011) Introduction to meta-analysis. Wiley, Hoboken"},{"key":"6126_CR36","volume-title":"Modern epidemiology","author":"TL Lash","year":"2020","unstructured":"Lash TL, Rothman KJ, VanderWeele TJ, Haneuse S (2020) Modern epidemiology. Wolters Kluwer, Philadelphia"},{"issue":"Suppl 1","key":"6126_CR37","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2022) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care 46(Suppl 1):S140\u2013S157. https:\/\/doi.org\/10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"issue":"4","key":"6126_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20(4):512\u2013522. https:\/\/doi.org\/10.1097\/EDE.0b013e3181a663cc","journal-title":"Epidemiology"},{"issue":"5","key":"6126_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15(5):291\u2013303. https:\/\/doi.org\/10.1002\/pds.1200","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"6126_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.12000","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami M, Ahr\u00e9n B, Dicembrini I, Mannucci E (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15(2):112\u2013120. https:\/\/doi.org\/10.1111\/dom.12000","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6126_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","volume":"99","author":"SV Wang","year":"2016","unstructured":"Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB (2016) Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther 99(3):325\u2013332. https:\/\/doi.org\/10.1002\/cpt.329","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"6126_CR42","doi-asserted-by":"publisher","first-page":"e019356","DOI":"10.1161\/jaha.120.019356","volume":"10","author":"RW Thomsen","year":"2021","unstructured":"Thomsen RW, Knudsen JS, Kahlert J et al (2021) Cardiovascular events, acute hospitalizations, and mortality in patients with type 2 diabetes mellitus who initiate empagliflozin versus liraglutide: a comparative effectiveness study. J Am Heart Assoc 10(11):e019356. https:\/\/doi.org\/10.1161\/jaha.120.019356","journal-title":"J Am Heart Assoc"},{"key":"6126_CR43","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.bonr.2022.101175","volume":"16","author":"M Rau","year":"2022","unstructured":"Rau M, Thiele K, Hartmann NK et al (2022) Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - data from a randomized, placebo-controlled study. Bone Rep 16:101175. https:\/\/doi.org\/10.1016\/j.bonr.2022.101175","journal-title":"Bone Rep"},{"issue":"10","key":"6126_CR44","doi-asserted-by":"publisher","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","volume":"4","author":"M Zhuo","year":"2021","unstructured":"Zhuo M, Hawley CE, Paik JM et al (2021) Association of sodium-glucose cotransporter\u20132 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw Open 4(10):e2130762. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.30762","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6126_CR45","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41(1):e4\u2013e5. https:\/\/doi.org\/10.2337\/dc17-1551","journal-title":"Diabetes Care"},{"issue":"10","key":"6126_CR46","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1111\/dom.14474","volume":"23","author":"M Fralick","year":"2021","unstructured":"Fralick M, Schneeweiss S, Redelmeier DA, Razak F, Gomes T, Patorno E (2021) Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: an observational study using data from routine care. Diabetes Obes Metab 23(10):2320\u20132328. https:\/\/doi.org\/10.1111\/dom.14474","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6126_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1210\/endrev\/bnz010","volume":"41","author":"Y Lytvyn","year":"2020","unstructured":"Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI (2020) The new biology of diabetic kidney disease\u2014mechanisms and therapeutic implications. Endocr Rev 41(2):202\u2013231. https:\/\/doi.org\/10.1210\/endrev\/bnz010","journal-title":"Endocr Rev"},{"issue":"11","key":"6126_CR48","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","volume":"40","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Ferrandino R, Chang A et al (2017) Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40(11):1479\u20131485. https:\/\/doi.org\/10.2337\/dc17-1011","journal-title":"Diabetes Care"},{"issue":"4","key":"6126_CR49","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2337\/dc18-1355","volume":"42","author":"SE Inzucchi","year":"2019","unstructured":"Inzucchi SE, Wanner C, Hehnke U et al (2019) Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42(4):e53\u2013e55. https:\/\/doi.org\/10.2337\/dc18-1355","journal-title":"Diabetes Care"},{"issue":"4","key":"6126_CR50","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.13184","volume":"20","author":"E Patorno","year":"2018","unstructured":"Patorno E, Gopalakrishnan C, Franklin JM et al (2018) Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab 20(4):974\u2013984. https:\/\/doi.org\/10.1111\/dom.13184","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06126-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:06:41Z","timestamp":1764266801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6126"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06126-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Some of the data were presented as an abstract at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in 2022.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Raw data used in the manuscript are not available to share due to the data user agreements in place but are available for purchase through the data vendors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was supported by a research grant to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim. The authors had full control of the design and conduct of the study and the interpretation of the study\u2019s findings. The authors retained the right of publication and determined the final wording of the manuscript. PTH was supported by a training grant (5T32DK007527) from the National Institute of Diabetes and Digestive and Kidney Diseases and is currently supported by a post-doctoral grant (4-22-PDFPM-15) from the American Diabetes Association. EP was supported by a career development grant (K08AG055670) from the National Institute on Aging and research grants from the Patient-Centered Outcomes Research Institute (DB-2020C2-20326) and the Food and Drug Administration (5U01FD007213).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PTH previously worked at Johnson & Johnson on unrelated work. SS reports investigator-initiated grants to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim International Gmbh, and owns equity in a software manufacturer, Aetion, Inc. DJW reports serving on data monitoring committees for Novo Nordisk, consulting for Elsevier and UpToDate, and grants from PCORI. BME reports consulting for Janssen, Eli Lilly and Company, Provention Bio, Ipsen Pharmaceuticals, the NIDDK, the American Heart Association and UptoDate; and grants from PCORI and Novo Nordisk outside the submitted work. RJG reports grants from Amgen, AstraZeneca, Kowa, Novartis and Pfizer outside the submitted work. LK is an employee of Eli Lilly and Company, and owns stock in Eli Lilly and Company. NS and AD-L are employees of Boehringer Ingelheim International GmbH. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors approved the final version to be published. PTH contributed to the study design, data analysis and initial development of the manuscript, and is the guarantor of this work. HT contributed to the data analysis and critical review of the manuscript. EP contributed to the study conception and design and critical review of the manuscript. DJW, JMP and BME contributed to the study conception and critical review of the manuscript. RJG and SS contributed to the study design, statistical input and critical review of the manuscript. NS, LK and AD-L participated in the study design, study conception and critical review of the manuscript. PTH and EP are responsible for the integrity of the work as a whole and are guarantors of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}